CN110585444A - 一种中西医结合药物及其制备方法与应用 - Google Patents

一种中西医结合药物及其制备方法与应用 Download PDF

Info

Publication number
CN110585444A
CN110585444A CN201911056365.5A CN201911056365A CN110585444A CN 110585444 A CN110585444 A CN 110585444A CN 201911056365 A CN201911056365 A CN 201911056365A CN 110585444 A CN110585444 A CN 110585444A
Authority
CN
China
Prior art keywords
chinese
western medicine
polymer
combination
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911056365.5A
Other languages
English (en)
Inventor
董军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201911056365.5A priority Critical patent/CN110585444A/zh
Publication of CN110585444A publication Critical patent/CN110585444A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明实施例公开了一种中西医结合药物及其制备方法与应用，所述中西医结合药物包括高分子多聚体，该高分子多聚体由多个单体结合而成；所述单体为蛋白类、糖类、核酸类、脂类、生物元素、有机物中的任意一种。本发明实施例提供的中西医结合药物包含由蛋白类、糖类、核酸类、脂类、生物元素、有机物单体结合而成的高分子多聚体，该中西医结合药物可在抗癌药物载体、缓释药物、促进伤口恢复、消炎药物筛选、以及伤科治疗中得到广泛应用，进一步丰富了中西医结合药物的种类，提高了治疗效果，促进了疾病的有效治疗。

Description

一种中西医结合药物及其制备方法与应用
技术领域
本发明涉及生物制药领域，具体涉及一种中西医结合药物及其制备方法与应用。
背景技术
中、西医药是各自独立的医药系统，中医药是中国传统医药，有数千年的发展历史，是中华文明的瑰宝。西医药是以科学实验和现代科技为基础的医药，是世界起主导作用的医药体系。随着现代医学的发展，中西医结合治疗疾病越来越广泛的被医家所应用，更多的患者选用中西药治疗，临床上中西药物配伍应用的情况也日趋普遍，中西药合理应用的确有提高疗效减少不良反应的优势。
目前，中西医结合药物的种类不多，治疗效果有限，不利于疾病的有效治疗。
发明内容
针对现有技术中的缺陷，本发明提供一种中西医结合药物及其制备方法与应用，能够进一步丰富中西医结合药物的种类，提高治疗效果，从而促进疾病的有效治疗。
为了实现上述目的，本发明实施例提供如下技术方案：
根据本发明实施例的第一方面，提供一种中西医结合药物，包括高分子多聚体，该高分子多聚体由多个单体结合而成；所述单体为蛋白类、糖类、核酸类、脂类、生物元素、有机物中的任意一种，所述蛋白类包含其组成单位及其衍生物，所述糖类包含各类单糖及其衍生物，所述核酸类包括各类核酸及其衍生物，所述脂类包括各种脂肪和类脂，所述生物元素包含生命过程中所必须的各种元素。
进一步的，所述的高分子多聚体包括聚乙二醇、聚乳酸-羟基乙酸共聚物、胶原蛋白、糖蛋白、核蛋白、热蛋白、藻酸盐、多羟基肯诺酸盐、琼脂糖、壳聚糖、聚乙酰氨基葡糖、透明质酸中的任意一种或两种以上的组合，但不限于此。
根据本发明实施例的第二方面，提供一种中西医结合药物的制备方法，包括采用物理方法、化学方法或两种方法的组合将多个单体合成高分子多聚体。
进一步的，所述的物理方法包括加热、加压、微波、红外、激光、电磁场中的任意一种或两种以上的组合；所述加热的方法包括蒸煮或烘烤，所述加压的方法包括磨研，但不限于此。
根据本发明实施例的第三方面，提供一种中西医结合药物作为抗癌药物载体的应用。
根据本发明实施例的第四方面，提供一种中西医结合药物在缓释药物中的应用。
根据本发明实施例的第五方面，提供一种中西医结合药物在促进伤口恢复中的应用。
根据本发明实施例的第六方面，提供一种中西医结合药物在消炎药物筛选中的应用，所述高分子多聚体含有多个阳离子，该高分子多聚体的pH≥8.0。
根据本发明实施例的第七方面，提供一种中西医结合药物在伤科治疗中的应用，所述高分子多聚体含有多个阴离子，该高分子多聚体的pH≤5.5。
根据本发明实施例的第八方面，提供一种抗菌药物，包括中西医结合药物。
本发明的有益效果体现在：本发明实施例提供一种中西医结合药物及其制备方法与应用，所述中西医结合药物包含由蛋白类、糖类、核酸类、脂类、生物元素、有机物单体结合而成的高分子多聚体，该中西医结合药物可在抗癌药物载体、缓释药物、促进伤口恢复、消炎药物筛选、以及伤科治疗中得到广泛应用，进一步丰富了中西医结合药物的种类，提高了治疗效果，促进了疾病的有效治疗。
具体实施方式
下面将结合具体实施例对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚地说明本发明的技术方案，因此只作为示例，而不能以此来限制本发明的保护范围。
需要注意的是，除非另有说明，本申请使用的技术术语或者科学术语应当为本发明所属领域技术人员所理解的通常意义，下述实施例中的实验材料，若无特别说明，均是来源于商业途径，所述的实验方法，若无特别说明，均为通用实验方法。
针对现有技术中的不足，本案发明人经长期研究和大量实践，得以提出本发明的技术方案，如下将对该技术方案、其实施过程及原理等作进一步的解释说明。
本发明实施例的一个方面提供了一种中西医结合药物，包括高分子多聚体，该高分子多聚体由多个单体结合而成；所述单体为蛋白类、糖类、核酸类、脂类、生物元素、有机物中的任意一种。
优选的，所述的高分子多聚体包括聚乙二醇、聚乳酸-羟基乙酸共聚物、胶原蛋白、糖蛋白、核蛋白、热蛋白、藻酸盐、多羟基肯诺酸盐、琼脂糖、壳聚糖、聚乙酰氨基葡糖、透明质酸中的任意一种或两种以上的组合，但不限于此。
本发明实施例的第二方面，提供一种中西医结合药物的制备方法，包括采用物理方法、化学方法或两种方法的组合将多个单体合成高分子多聚体。
优选的，所述的物理方法包括加热、加压、微波、红外、激光、电磁场中的任意一种或两种以上的组合；所述加热的方法包括蒸煮或烘烤，所述加压的方法包括磨研，但不限于此。
本发明实施例的第三方面，提供一种中西医结合药物作为抗癌药物载体的应用。
优选的，提供一种治疗癌症的药物，包括所述的高分子多聚体和抗癌活性分子。
优选的，提供一种癌症的区域性放射治疗方法，包括将所述的高分子多聚体与放射性物质结合使用。
本发明实施例的第四方面，提供一种中西医结合药物在缓释药物中的应用；优选的，所述缓释药物包括缓释胶囊，但不限于此。
本发明实施例的第五方面，提供一种中西医结合药物在促进伤口恢复中的应用。
本发明实施例的第六方面，提供一种中西医结合药物在消炎药物筛选中的应用，所述高分子多聚体含有多个阳离子，该高分子多聚体的pH≥8.0。
本发明实施例的第七方面，提供一种中西医结合药物在伤科治疗中的应用，所述高分子多聚体含有多个阴离子，该高分子多聚体的pH≤5.5。
本发明实施例的第八方面，提供一种抗菌药物，包括中西医结合药物。
实施例1
本实施例提供一种中西医结合药物，包括高分子多聚体，该高分子多聚体由多个单体结合而成；所述单体为蛋白类、糖类、核酸类、脂类、生物元素、有机物中的任意一种。
优选的，所述高分子多聚体包括聚乙二醇、聚乳酸-羟基乙酸共聚物、胶原蛋白、糖蛋白、核蛋白、热蛋白、藻酸盐、多羟基肯诺酸盐、琼脂糖、壳聚糖、聚乙酰氨基葡糖、透明质酸中的任意一种或两种以上的组合，但不限于此。
实施例2
本实施例提供一种中西医结合药物的制备方法，包括采用物理方法、化学方法或两种方法的组合将多个单体合成高分子多聚体。所述的物理方法包括加热、加压、微波、红外、激光、电磁场中的任意一种或两种以上的组合；所述加热的方法包括蒸煮或烘烤，所述加压的方法包括磨研，但不限于此。
实施例3
在采取实施例1技术方案的基础上，本实施例提供一种中西医结合药物在抗癌药物载体、缓释药物、促进伤口恢复、消炎药物筛选、以及伤科治疗中得到广泛应用，进一步丰富了中西医结合药物的种类，提高了治疗效果，促进了疾病的有效治疗。
以下结合具体案例，对本发明进行详细说明。
案例1、抗癌物质目前已知的有10多种，紫杉醇是其中一种，单独使用毒性较高，通过将紫杉醇与白蛋白结合，制成最佳抗乳腺癌药物，广泛应用于临床。
案例2、聚乙二醇的单体是乙二醇，有毒性，聚合以后，毒性消失。聚乙二醇与治疗药物结合，利用其可在体内逐步分解的特点，制作为缓释药物或胶囊，糖尿病治疗的长效原理也是该原理的运用。
案例3、富含阴离子高分子多聚物如多聚蛋白类，其ph值低于5.5者具备开发创伤修复药物的基础，可用于各类伤科的治疗药物的开发，如普通外科药物。
案例4、部分蛋白类，糖类如壳聚糖，含阳离子或多阳离子，银离子本身是阳离子，这些都是开发抗菌消炎药物的基础。它们可以和细菌细胞壁的阴离子结合，从而阻碍细菌细胞壁的合成，造成细菌死亡，达到抗菌效果。
需要说明的是，药物研发需要合理搭配各组分，有毒物质的产生与检测是研发者自己的责任，后果自负。
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围，其均应涵盖在本发明的权利要求和说明书的范围当中。

Claims (10)

1.一种中西医结合药物，其特征在于：包括高分子多聚体，该高分子多聚体由多个单体结合而成；所述单体为蛋白类、糖类、核酸类、脂类、生物元素、有机物中的任意一种。
2.根据权利要求1所述的中西医结合药物，其特征在于：所述的高分子多聚体包括聚乙二醇、聚乳酸-羟基乙酸共聚物、胶原蛋白、糖蛋白、核蛋白、热蛋白、藻酸盐、多羟基肯诺酸盐、琼脂糖、壳聚糖、聚乙酰氨基葡糖、透明质酸中的任意一种或两种以上的组合。
3.一种如权利要求1—2中任一项所述中西医结合药物的制备方法，其特征在于：包括采用物理方法、化学方法或两种方法的组合将多个单体合成高分子多聚体。
4.根据权利要求3所述的制备方法，其特征在于：所述的物理方法包括加热、加压、微波、红外、激光、电磁场中的任意一种或两种以上的组合；所述加热的方法包括蒸煮或烘烤，所述加压的方法包括磨研。
5.一种如权利要求1—2中任一项所述中西医结合药物作为抗癌药物载体的应用。
6.一种如权利要求1—2中任一项所述中西医结合药物在缓释药物中的应用。
7.一种如权利要求1—2中任一项所述中西医结合药物在促进伤口恢复中的应用。
8.一种如权利要求1—2中任一项所述中西医结合药物在消炎药物筛选中的应用，其特征在于：所述高分子多聚体含有多个阳离子，该高分子多聚体的pH≥8.0。
9.一种如权利要求1—2中任一项所述中西医结合药物在伤科治疗中的应用，其特征在于：所述高分子多聚体含有多个阴离子，该高分子多聚体的pH≤5.5。
10.一种抗菌药物，其特征在于：包括权利要求1—2中任一项所述的中西医结合药物。
CN201911056365.5A 2019-10-31 2019-10-31 一种中西医结合药物及其制备方法与应用 Pending CN110585444A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911056365.5A CN110585444A (zh) 2019-10-31 2019-10-31 一种中西医结合药物及其制备方法与应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911056365.5A CN110585444A (zh) 2019-10-31 2019-10-31 一种中西医结合药物及其制备方法与应用

Publications (1)

Publication Number Publication Date
CN110585444A true CN110585444A (zh) 2019-12-20

Family

ID=68852383

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911056365.5A Pending CN110585444A (zh) 2019-10-31 2019-10-31 一种中西医结合药物及其制备方法与应用

Country Status (1)

Country Link
CN (1) CN110585444A (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1448128A (zh) * 2002-03-29 2003-10-15 艾斯·多伯法股份公司 制备紫杉醇和白蛋白的纳米颗粒的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1448128A (zh) * 2002-03-29 2003-10-15 艾斯·多伯法股份公司 制备紫杉醇和白蛋白的纳米颗粒的方法

Similar Documents

Publication Publication Date Title
Li et al. Systematic analysis of tRNA-derived small RNAs reveals novel potential therapeutic targets of traditional Chinese medicine (Buyang-Huanwu-Decoction) on intracerebral hemorrhage
Andrgie et al. Ibuprofen-loaded heparin modified thermosensitive hydrogel for inhibiting excessive inflammation and promoting wound healing
CN108175765A (zh) 一种酸敏控释抗炎凝胶及其制备方法与应用
BRPI0517426A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
Song et al. Biopharmaceutical applications of microbial polysaccharides as materials: a review
Santinon et al. Evaluation of different covalent crosslinking agents into valsartan-loaded sericin and alginate particles for modified release
CN104892917B (zh) 氨基葡萄糖修饰的聚乙二醇‑聚乳酸及其制备方法和应用
Zhao et al. Recent advances of natural-polymer-based hydrogels for wound antibacterial therapeutics
CN104586821B (zh) 一种负载铂类药物的水凝胶体系及其制备方法
del Olmo et al. Sustained drug release from biopolymer-based hydrogels and hydrogel coatings
CN110585444A (zh) 一种中西医结合药物及其制备方法与应用
Azhari Rad et al. Tissue Engineering Scaffolds Loaded With a Variety of Plant Extracts: Novel Model in Breast Cancer Therapy
US20190184019A1 (en) Hydrogel and preparation method thereof
CN106177987A (zh) 小分子‑高分子轭合物自组装载药纳米颗粒及其制备方法
Yang et al. Polymer-Based Wound Dressings Loaded with Ginsenoside Rg3
Xie et al. Cu–Tremella fuciformis polysaccharide–based tumor microenvironment–responsive injectable gels for cuproptosis-based synergistic osteosarcoma therapy
CN105199115B (zh) 一种多孔渗水的三维网状结构的可注射水凝胶的制备及其应用
Yang et al. Advances in the Study of Liposomes Gel with Stimulus Responsiveness in Disease Treatment
CN104971345B (zh) 一种治疗烧烫伤的大黄素明胶微球与纳米银复合凝胶制剂
CN104147197A (zh) 一种治疗足癣的药物及其制备方法
CN102008714B (zh) 一种促进冻疮结痂后快速愈合的药膏
CN109010316A (zh) 一种维生素b6缓释制剂的制备方法
CN108721254A (zh) 一种紫杉醇-n-琥珀酰羟乙基壳聚糖高分子药物长效缓释膜片及其制备方法
Kim et al. Preparation of azidophenyl-low molecular chitosan derivative micro particles for enhance drug delivery
CN108379391B (zh) 一种治疗造影后恶心呕吐的药物组合物及制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191220